These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Molecular biology and clinical applications to cancer. Lotze MT Curr Opin Gen Surg; 1994; ():245-54. PubMed ID: 7583982 [TBL] [Abstract][Full Text] [Related]
43. [Genetic aspects of neoplasia]. Shapot VS Arkh Patol; 1981; 43(2):5-13. PubMed ID: 7013737 [TBL] [Abstract][Full Text] [Related]
44. Models of tumor-host interaction as competing populations: implications for tumor biology and treatment. Gatenby RA J Theor Biol; 1995 Oct; 176(4):447-55. PubMed ID: 8551743 [TBL] [Abstract][Full Text] [Related]
45. Genomic alterations in solid tumors. Introduction. Imreh S Semin Cancer Biol; 1999 Aug; 9(4):241-4. PubMed ID: 10448111 [No Abstract] [Full Text] [Related]
46. Cytogenetic abnormalities in cancer: with special emphasis on tumor heterogeneity. Pathak S Cancer Metastasis Rev; 1990 Feb; 8(4):299-318. PubMed ID: 2182210 [TBL] [Abstract][Full Text] [Related]
47. [Pathogenesis of the tumor process]. Anichkov NM Arkh Patol; 1988; 50(1):3-11. PubMed ID: 3284511 [TBL] [Abstract][Full Text] [Related]
48. Integrating germline and somatic data towards a personalized cancer medicine. Pujana MA Trends Mol Med; 2014 Aug; 20(8):413-5. PubMed ID: 25086750 [TBL] [Abstract][Full Text] [Related]
50. [Individuality of malignant neoplasms]. Leder LD Strahlenther Onkol; 1986 Oct; 162(10):624-8. PubMed ID: 3535141 [TBL] [Abstract][Full Text] [Related]
51. [Advances in research on the molecular pathogenesis of the malignant tumours and implications for their early diagnosis and treatment]. Steffen J Med Wieku Rozwoj; 2000; 4(2 Suppl 2):11-25. PubMed ID: 11178325 [TBL] [Abstract][Full Text] [Related]
52. Role of germline genetic factors in MPN pathogenesis. Harutyunyan AS; Kralovics R Hematol Oncol Clin North Am; 2012 Oct; 26(5):1037-51. PubMed ID: 23009936 [TBL] [Abstract][Full Text] [Related]
54. [Effect of molecular diagnostic procedures on surgical therapy of malignant diseases]. von Knebel Doeberitz M; Gebert J; Herfarth C Chirurg; 1996 Oct; 67(10):967-79. PubMed ID: 9011428 [TBL] [Abstract][Full Text] [Related]
55. Chromothripsis in cancer cells: An update. Rode A; Maass KK; Willmund KV; Lichter P; Ernst A Int J Cancer; 2016 May; 138(10):2322-33. PubMed ID: 26455580 [TBL] [Abstract][Full Text] [Related]
56. Molecular targets and clinical cancer risk reductive interventions. Kakarala M; Brenner DE Prog Mol Biol Transl Sci; 2010; 95():351-75. PubMed ID: 21075336 [No Abstract] [Full Text] [Related]
57. Germ line polymorphism in metastatic progression. Hunter KW; Crawford NP Cancer Res; 2006 Feb; 66(3):1251-4. PubMed ID: 16452174 [TBL] [Abstract][Full Text] [Related]
58. Normal Somatic Mutations in Cancer Transformation. Wijewardhane N; Dressler L; Ciccarelli FD Cancer Cell; 2021 Feb; 39(2):125-129. PubMed ID: 33220180 [TBL] [Abstract][Full Text] [Related]
59. Defining the Influence of Germline Variation on Metastasis Using Systems Genetics Approaches. Lee M; Crawford NP Adv Cancer Res; 2016; 132():73-109. PubMed ID: 27613130 [TBL] [Abstract][Full Text] [Related]